ABSTRACT OBJECTIVE: Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a disorder characterized by debilitating fatigue accompanied by pain and impairments in memory, cognition, and concentration. Acetylcholine (ACh) has a plethora of roles in neuronal and neuromuscular transmission. There are two types of ACh receptors, muscarinic and nicotinic, comprising 17 different subunits of the nicotinic ACh receptor (nAChR) and five different subtypes of the muscarinic receptor (mAChR) that have been identified in humans. The purpose of this study was to determine the role of ACh receptor (nAChRs and mAChRs) single nucleotide polymorphisms (SNPs) in CFS/ME patients. METHODS: One-hundred and fifteen CFS/ME patients (age = 48.68 ± 1.06 years) and 90 nonfatigued controls (age = 46.48 ± 1.22 years) participated in this study, where CFS/ME patients were defined according to the 1994 Center for Disease Prevention and Control (CDC) criteria. A total of 464 SNPs for nine mammalian ACh receptor genes (M1, M2, M3, M4, M5, alpha 2, 5, 7, and 10) were examined via the Agena Biosciences iPLEX Gold assay. Statistical analysis was performed using the PLINK analysis software. RESULTS: Seventeen SNPs were significantly associated with CFS/ME patients compared with the controls. Nine of these SNPs were associated with mAChRM3 (rs4463655; P = 0.00281, rs589962; P = 0.00348, rs1072320; P = 0.00371, rs7543259; P = 0.00513, rs6661621; P = 0.00536 rs7520974; P = 0.0167, rs726169; P = 0.02349, rsrs6669810; P = 0.02361, rsrs6429157; P = 0.0375), while the remainder were associated with nAChR alpha 10 (rs2672211; P = 0.0107, rs2672214; P = 0.0108, rs2741868; P = 0.01185, rs2741870; P = 0.01281, rs2741862; P = 0.03043), alpha 5 (rs951266; P = 0.01153; rs7180002, P = 0.03682), and alpha 2 (rs2565048; P = 0.01403).
Introduction
The physiological functions of acetylcholine (ACh) are mediated by two membrane proteins, namely, the muscarinic (mAChR) and nicotinic (nAChR) receptors. Both receptor types have several subtypes and are located in the central and peripheral nervous systems, including the autonomic nervous system. ACh also performs functions in smooth muscle, sweat glands, b pancreatic cells, glial cells, lymphocytes, ocular lens cells, brain vascular endothelium, 1 and the central nervous system (CNS). [2] [3] [4] [5] [6] The degradation of ACh into choline and acetate is catalyzed by the enzyme acetylcholinesterase (AChE). 7, 8 There are five main mAChR subtypes: M1, M2, M3, M4, and M5, where M2 and M4 are inhibitory receptors, and M1, M2, and M3 are stimulatory receptors. 7, 8 Once activated, each subtype has distinctive functions. Activation of M1, M3, and M5 receptors results in increased intracellular calcium signaling. In contrast, activated M2 and M4 receptors inhibit adenylate cyclase activity and mediate the function of nonselective cation channels, transient receptor potential channels, and potassium channels. [7] [8] [9] [10] nAChRs are fast ionotropic cationic nicotinic receptor channels that allow the influx of cations such as potassium, calcium, and sodium ions into the cell. Depending upon the combinational subunit binding, AChRs can form either heteromers or homomers.
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Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a disorder characterized by debilitating fatigue accompanied by impairments in memory, cognition, and concentration as well as pain and dysregulation of the gastrointestinal, cardiovascular, and immune systems. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] Importantly, peripheral cholinergic function is noted to be abnormal in CFS/ME patients exposed to ACh challenge, whereby blood flow peaks take a longer time to return to normal. Increased sensitivity to ACh is noted in peripheral vascular endothelium. 30, 31 ACh influences immune cell function 32 and is manufactured and secreted by a wide range of immune cells including lymphocytes. [32] [33] [34] [35] We, along with others, have reported changes in immune cell phenotype and function as well as noting cardiac and neurological effects in disease.
14-16,18-20,22,24,26,27,29 Additionally, we have reported single nucleotide polymorphisms (SNPs) in transient receptor potential (TRP) ion channels in CFS/ ME patients. 36 SNPs occur in the coding sequences, noncoding regions, or intergenic regions of genes, where these SNPs, depending upon their location and the influence of additional splicing mechanisms, may lead to human disease. 10, 11, [14] [15] [16] [18] [19] [20] 22, 24, 26, 27, 29 Given these collective reports and the role of TRPs and AChRs in cellular functions, the aim of the current study was to examine SNPs in AChRs in the same cohort of CFS/ME patients in whom we had previously reported TRP SNP anomalies.
Methodology
Subjects. CFS patients were defined in accordance with the 1994 Center for Disease Prevention and Control (CDC) criteria for CFS. 37 A total of 115 CFS patients and 90 nonfatigued controls were recruited for this study, and a volume of 10 mL of whole blood was collected from all participants in EDTA tubes. Written consent was obtained from all participants prior to the collection of samples and this research was approved by Griffith University Human Research Ethics Committee (MSC/18/13/HREC) in accordance with the National Human Research Ethical Standards and in accordance with the Declaration of Helsinki.
DNA extraction. Genomic DNA was extracted from all whole-blood samples using the Qiagen DNA blood minikit as per manufacturer's instructions (Qiagen). Quality and quantity of the DNA extracted were determined by the The Nanodrop (Nanodrop), where approximately 2 μg of genomic DNA was used to perform the SNP assay.
SNP genotyping studies. Geneworks completed the SNP analysis as previously defined (MassARRAY iPLEX Gold Assay). 38 Customized assays were developed for 464 SNPs across the nine mammalian acetylcholine receptor genes (M1, M2, M3, M4, M5, alpha 2, 5, 7, and 10), which were selected because of the locations of these receptors in the central and peripheral nervous system, endocrine system, smooth muscle cells, b pancreatic cells, glial cells, lymphocytes, ocular lens cells, and brain vascular endothelium. [1] [2] [3] [4] [5] [6] Primers and extension primers were created for each of the SNPs using the Assay Designer 38 according to the manufacturer's instructions. The amplification of the DNA was done as previously described. 39 Briefly, DNA was amplified via polymerase chain reaction (PCR) under the following conditions: 94°C for 2 minutes, 94°C for 30 seconds, 56°C for 30 seconds, and 72°C for 1 minute. Amplification products were then treated with shrimp alkaline phosphatase (SAP) at 37°C for 40 minutes, 85°C for 5 minutes reaction, and a final incubation at 4°C. Extension primers were optimized to control the signal-tonoise ratio where unextended primers (UEPs) were examined on the spectroCHIP and evaluated in Typer 4.0 to enable the division into low-mass, medium-mass, and high-mass UEPs. To perform the iPLEX extension reaction, a mixture containing iPLEX Gold reaction was prepared using iPLEX Gold Buffer Plus, iPLEX termination mix, iPLEX enzyme, and primer mix. The iPLEX reaction was cycled at an initial denaturation of 94°C for 30 seconds, annealing at 52°C for 5 minutes, extension at 80°C for 5 minutes (5 cycles of annealing and extension were performed, but the whole reaction was performed in 40 cycles), and extension again at 72°C for 3 minutes. Resin beads were used to rinse all iPLEX Gold reaction products. Following iPLEX Gold reaction, MassARRAY was performed using the MassARRAY mass spectrometer, and the data generated were analyzed using the TyperAnalyzer software.
Statistical analysis. The PLINK v1.07 40 whole-genome analysis toolset was implemented to determine the association between the CFS patients and the nonfatigued control group. A two-column χ 2 test was used, where the alpha level of significance was set at a P-value of 0.05.
Results
Participants. A total of 115 CFS patients (age = 48.68 ± 1.06 years) comprising 84 (73.04%) women and 31 (26.96%) men were recruited. The 90 nonfatigued controls (age = 46.48 ± 1.22 years) comprised 59 (65.56%) women and 31 (34.44%) men. All participants in both groups were of European descent. All participants were aged between 25 and 65 years and some of them were excluded following any symptoms and their replies in the affirmative to a medical questionnaire comprising whether they were taking any medications; showing signs of a comorbid chronic illness such as cardiovascular disease, diabetes, or autoimmune diseases; had been previously diagnosed with psychosis or epilepsy; or were pregnant, breastfeeding, or smokers. Furthermore, the nonfatigued controls were excluded if they reported symptoms of fatigue after completing the medical and symptom questionnaires. 15, 17 All were residents of Australia at the time of blood collection.
SNP association studies. Of the 464 SNPs examined in the present study, 393 were successfully identified in both participants groups. Of the 393, seventeen were observed to be significantly associated with CFS (Table 1) . Nine of these SNPs were associated with mAChRM3 (rs4463655; P = 0.00281, rs589962; P = 0.00348, rs1072320; P = 0.00371, rs7543259; P = 0.00513, rs6661621; P = 0.00536, rs7520974; P = 0.0167, rs726169; P = 0.02349, rsrs6669810; P = 0.02361, rsrs6429157; P = 0.0375), while the remainder were associated with nAChR alpha 10 (rs2672211; P = 0.0107, rs2672214; P= 0.0108, rs2741868; P = 0.01185, rs2741870; P = 0.01281, rs2741862; P = 0.03043), alpha 5 (rs951266; P = 0.01153; rs7180002, P = 0.03682), and alpha 2 (rs2565048; P = 0.01403). A summary of the SNPs that were not significant is given in Supplementary Table 1. ) for basic allelic test (1df), and P-value for this test set at a significance of P  0.05.
Discussion
This pilot study revealed a number of AChR SNP variations in CFS/ME patients. Specifically, within the coding sequences of nine AChR genes out of 464 SNPs examined, 17 significant alleles were found associated with CFS/ME patients compared to the nonfatigued controls. Moreover, these alleles were located in the gene sequence of one of the muscarinic acetylcholine receptors (mAChRM3) and three nicotinic acetylcholine alpha receptors (nAChRα2, nAChRα5, and nAChRα10). Interestingly, in our previous study, we identified a number of SNPs in the TRP family, namely, TRPM3. The importance of SNPs in mAChRM3 and TRPM3 is that the latter couples with mAChRM3 and can be activated by ACh. [41] [42] [43] There is limited information available on the role of these AChR SNPs. However, alternate splicing in the noncoding sequences may have significant, unexpected outcomes on the splicing mechanism of the gene transcripts. 44, 45 Splicing genetic variants that are intronic variants play a role in alternative splicing mechanisms, resulting in diverse protein isoforms. Incidentally, the human gene has the largest average number of mRNA isoforms per gene, 46 with an average of seven isoforms. 47, 48 Additionally, enhancers and silencers that are located in the introns are integral to the recognition of the correct exon sequence 49 for correct protein coding. Also, introns have been documented to generate active spliceosomes, giving rise to alternative splicing events.
50,51 Importantly, our data show that the proportion of intron variants in the SNP has been previously reported to be associated with smooth muscle and respiratory function (rs4463655, rs589962, rs1072320, rs7543259, and rs6661621), neurocognitive function (rs951266), neuropathic pain (rs2741868), and gastric function (rs7520974). 52, 53 Additionally, in the current study, we report SNP rs6669810 in CFS/ME patients, which is responsible for the gene ART1, an ADP-ribosyltransferase that catalyzes the ADP-ribosylation of arginine residues in proteins. Mono-ADP-ribosylation is a posttranslational modification of proteins affected by a variety of bacterial toxins, including cholera, pertussis, and heat-labile enterotoxins of Escherichia coli. Interestingly, previous researchers have reported increases in viral loads, respiratory-associated illnesses, neurocognitive changes, and neuropathic pain from CFS/ME patients.
54-57
SNPs were found in mAChR receptors, and are responsible for initiating smooth muscle contraction, such as in the gastrointestinal and genitourinary tracts, as well as effects in immune cells, epithelial, ovarian, and ocular skin cells, and respiratory and secretory glands.
5,32-35,58-67 Additionally, nAChRs are reported on T and B lymphocytes.
68,69 Human T lymphocytes express the α3, α4, α7, b2, and b4 receptor subunits, 70 while in the mouse and human thymus mAChR expression has been found to play a role in T-lymphocyte development and proliferation.
68,71-73 The α4 or α7 subunits have also been reported on B lymphocytes and found to stimulate proliferation while decreasing antibody production. 74 Such findings provide possible insight regarding the SNPs found in the current paper, noting that previous investigations have reported compromise to immune function in CFS/ ME patients. Importantly, changes in numbers and function of lymphocytes, such as natural killer (NK) lymphocytes and T and B lymphocytes, in these studies suggest increased influx of Ca 2+ .
The mAChRM3 receptors are located in the gastrointestinal tract and are controlled in part by the parasympathetic nervous system through the vagus nerve. 75 Moreover, clinical data report that nAChRs are involved in inflammatory bowel disease.
76 CFS/ME patients often exhibit gastrointestinalassociated issues, such as irritable bowel syndrome and constipation.
12,28
Dysregulation of mAChRM3 receptors may affect metabolic and cardiac responses. In normal pancreas, mAChRM3 receptors play a role in regulating insulin and glucagon secretion.
77,78 Muscarinic ACh receptors expressed by pancreatic b cells have been reported to play a significant role in maintaining proper insulin release and whole-body glucose homeostasis. 77 Changes in Ca 2+ -mediated channels may result in adverse glucose metabolic outcomes as implied in CFS/ME patients. 79 Pancreatic b cells rely on transient changes in Ca
2+
to initiate the complex sequence of events resulting in insulin secretion following glucose exposure. Thus, it may be argued that aberrant intracellular Ca 2+ concentrations through permissive AChR activity will impede the usual and necessary sequence of events required to initiate insulin response to glucose in CFS patients.
Cardiac mAChRM3 receptors perform an array of pathological and physiological functions. mAChM2 is not the only muscarinic receptor involved in cardiac function. Rather, mAChRM3 parasympathetic control of cardiac function is well established. 48 A report by van Borren et al 80 has shown the effect of muscarinic AChR stimulation on Ca 2+ transients, cAMP production, and pacemaker frequency in sinoatrial (SA) nodes of the rabbit. These findings imply that muscarinic agonism will have an effect on SA node function, exacerbating disturbances of proper cardioregulatory mechanisms, particularly in an environment where Ca 2+ intracellular concentrations are likely to be altered due to the direct effects of receptor activity. Clinical consequences such as altered orthostatic cardiovascular responses could be predicted and could align with symptom presentation in CFS/ME. 13, 21, 25, 27, 29 In the vascular system, the endothelium contains nAChRs, including α3, α5, α7, α10, b2, b3, and b4.
63,81,82
Depending upon the type of smooth muscle, a specific subtype of nAChR is present: α3 and α5 are found in arteries, while α7 is widespread although not present in the renal circulatory system. nAChR α5, α7, b2, and b3 have been found in brain endothelial cells 83 and are an important component of the blood-brain barrier. This study identified SNPs in the α5 and α3 nAChR subunits, implying anomalies of signal transduction in our patient cohort. nAChRs are reported to be involved in arousal, sleep, and fatigue as well as those functions that are responsible for processing of pain, memory, and cognition.
84-86

Conclusion
In conclusion, we report for the first time the presence of SNPs in receptors for ACh in patients with CFS/ME. Many detrimental consequences for physiological homeostasis are possible through aberrant AChR function in these patients. These scenarios require further investigation to establish whether the AChR SNPs identified in this study result in changes of function and conceivably may be associated with CFS/ME pathomechanisms and symptomatology. 
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